NEW YORK (GenomeWeb News) – Toxicology and genetics lab Physician's Choice Laboratory Services has acquired the CertNDx Bladder Cancer diagnostic testing assets from Predictive Biosciences for an undisclosed amount. The CertNDx Bladder Cancer Assay is a urine-based test that uses protein biomarkers and molecular DNA analysis to detect the presence or absence of urothelial cancer in patients presenting with hematuria. It stratifies patients based on their likelihood of bladder cancer and disease progression.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.